Anti-Venom Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 1.20 Billion |
| Market Size (2029) | USD 1.40 Billion |
| CAGR (2024 - 2029) | 3.13 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Anti-Venom Market Analysis
The Anti-venom Market size is estimated at USD 1.20 billion in 2024, and is expected to reach USD 1.40 billion by 2029, growing at a CAGR of 3.13% during the forecast period (2024-2029).
During the COVID-19 epidemic, there was a considerable increase in the number of deaths reported from snake bites in a few regions. This caused a significant need for anti-venoms. However, shifting priorities due to the pandemic in already vulnerable health systems impacted snakebite care on all levels. According to the study published in the British Medical Journal in October 2021, after the COVID-19 pandemic was proclaimed in 2020, an estimated 2.7 million cases of snakebite envenoming (SBE) caused over 100,000 fatalities and 400,000 long-term impairments across Asia, Africa, and Latin America's poorest and most rural communities. Such studies greatly highlighted the treatment gap amid the outbreak. On the other hand, the market is expected to grow at a stable pace in the post-pandemic phase with the emerging strains of the SARS-CoV-2 virus worldwide. For instance, according to the study published by Cold Spring Herber Laboratory in January 2022, snake venom phospholipases A2 were found to have high virucidal activity against SARS-CoV-2 in vitro and to prevent cell fusion mediated by spike glycoprotein binding with the ACE2 receptor. Thus, as per the analysis, such instances are likely to augment the demand for anti-venoms among COVID-19 patients, in turn propelling the market's growth over the forecast period.
The studied market growth can largely be attributed to factors such as the increasing awareness of anti-venoms available in the market, the surge in cases of venomous bites, and technological advancements. Snakebite is one of the most neglected public health issues in many tropical and subtropical countries. According to the May 2021 update by the WHO, approximately 5.4 million snake bites occur each year, resulting in up to 2.7 million envenomings (poisonings from snake bites) and about 81,000 to 138,000 deaths. Moreover, it often leads to around three times as many amputations and other permanent disabilities. According to the August 2022 report "Accidental Deaths & Farm Suicides in India," 10,450 snakebite cases were reported in India in 2021, with 10,382 individuals dying and 64 injured. Furthermore, the data indicated that in 2021, Madhya Pradesh scored first in terms of snake bite deaths (2,732), followed by Odisha (1,019), Chhattisgarh (909), and Uttar Pradesh (844). Thus, the growing incidence of snake bites is expected to increase demand for anti-venom treatment, thereby boosting the growth of the market.
Furthermore, the prevalence of venomous bites and stings has increased over the years. To cater to the demand for anti-venom drugs, market players are opting for many initiatives to strengthen their market presence. For instance, in September 2021, a partnership between Papua New Guinea (PNG) and Australia to donate anti-venom and help save the lives of people bitten or stung by venomous snakes and marine creatures was extended for a further two years, 2021-2023. This will increase the accessibility of anti-venomous drugs across countries, thus driving the market growth.
However, anti-venom production is difficult and expensive. The cost of anti-venom has increased over the last two decades, making treatment unaffordable for most people. This is expected to hinder market growth over the forecast period.
Anti-Venom Market Trends
The Polyvalent Anti-venoms Segment is Expected to Hold Significant Share in the Market Over the Forecast Period
Polyvalent anti-venoms consist of antibodies that are capable of counteracting several homologous venoms from various species/genera. Polyvalent snake antivenom contains the active ingredients brown snake antivenom, tiger snake antivenom, death adder antivenom, taipan antivenom, and black snake antivenom. Polyvalent antivenoms can save the lives of victims of snake envenomation, even when the culprit snake is unknown and a monovalent antivenom cannot be chosen. Due to the obvious advantages that they have, polyvalent anti-venoms are the most preferred anti-venom drug.
Polyvalent anti-venoms are beneficial in regions where there is a large presence of venomous species and when it is difficult to produce monovalent anti-venoms against all of them. Owing to the numerous advantages, the key players dealing in the anti-venom market are focusing on developing polyvalent anti-venoms.
Furthermore, rising research and development activities proving the efficacies of existing treatments are further expected to drive the studied segment. For instance, according to the study published in Toxin Basel in October 2021, two Indian polyvalent anti-venoms, VINS and Bharat, showed positive results in preventing or reversing in vitro myotoxicity induced by common cobra (Naja naja) venom from Sri Lanka and hence can be proactively used as a therapeutic in treating cobra bites.
As a result of the aforementioned factors, such as the advantages of polyvalent anti-venom and expanding research and development activities, the segment's growth is expected to accelerate over the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
The North American anti-venom market is expected to hold a significant share during the forecast period, owing to the high incidence of snake bites and other venomous bites in the region, the rise in awareness of venomous bites, and rising technological advancements. The United States within North America is expected to contribute significantly to the market growth in the region. As per the June 2021 article by the CDC, each year, an estimated 7,000-8,000 people are bitten by venomous snakes in the United States, and about five of those people die. Workers are far more likely to suffer long-term injuries from snake bites than to die from them. Thus, due to the high prevalence of snake bites in the country, the demand for its therapeutics is expected to increase, thereby boosting the market's growth.
Moreover, product approvals and strategic initiatives by key market players are also expected to augment market growth in the country. For instance, in March 2022, Ophirex, Inc., announced that the US FDA had granted Fast Track designation to varespladib-methyl ("oral varespladib") for the treatment of snakebite. Ophirex is currently conducting a clinical trial of oral varespladib, its lead investigational drug candidate, as a broad-spectrum snakebite antidote in the United States and India.
Furthermore, in April 2021, Rare Disease Therapeutics, Inc. announced that the US FDA approved a new expanded indication for ANAVIP (crotalidae immune F(ab')2 (equine)), an equine-derived antivenin, for the management of adult and pediatric patients with North American pit viper envenomation.
Thus, due to the above-mentioned factors, such as the high prevalence of snake bites and strategic initiatives by market players, the market in the North American region is expected to witness strong growth over the forecast period.
Anti-Venom Industry Overview
The anti-venom market is competitive, and consists of several market players. Most developing countries with established biotechnological facilities have local scientific expertise, which creates favorable conditions and the atmosphere to establish local anti-venom manufacturing practices. Countries such as Brazil, Costa Rica, Egypt, France, India, Mexico, South Africa, and Thailand have large, well-established anti-venom manufacturers. The major market players operating in the anti-venom market include BTG PLC, Pfizer Inc., Merck KGaA (Sigma Aldrich), Boehringer Ingelheim, and CSL Limited, among others.
Anti-Venom Market Leaders
-
Pfizer Inc.
-
Merck KGaA (Sigma Aldrich)
-
Boehringer Ingelheim
-
CSL Limited
-
Bharat Serums and Vaccines Ltd
*Disclaimer: Major Players sorted in no particular order
Anti-Venom Market News
- In July 2022, the foundation of the Antivenom Research and Development Centre (AVRDC) was laid at the Institute of Bioinformatics and Applied Biotechnology (IBAB), Bengaluru Helix Biotech Park, Electronics City, to boost the production activities for antivenom.
- In April 2022, the complementary agreement to the technical cooperation agreement between Brazil and the government of the Republic of the Union of Myanmar for the implementation of the project "Improving methodologies and techniques for the production of antivenom serum in Myanmar - phase II: antivenom quality" was signed. The goal of the project is to increase the quality and performance of the antivenom serum produced in that Asian country.
Anti-Venom Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Awareness on Anti-venoms Available
- 4.2.2 Technological Advancements
-
4.3 Market Restraints
- 4.3.1 Complexities Involved in the Preparation of the Correct Immunogens
- 4.3.2 Lack of Regulatory Capacity for the Control of Anti-venoms in Countries
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - in USD Million)
-
5.1 By Species
- 5.1.1 Snake
- 5.1.2 Scorpion
- 5.1.3 Spiders
- 5.1.4 Other Species
-
5.2 By Anti-venom Type
- 5.2.1 Polyvalent Anti-venoms
- 5.2.2 Monovalent Anti-venom
- 5.2.3 Other Anti-venom Types
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Bharat Serums and Vaccines Ltd
- 6.1.2 Boehringer Ingelheim International GmbH
- 6.1.3 Boston Scientific Corporation
- 6.1.4 CSL Limited
- 6.1.5 Flynn Pharma Ltd (Micropharm)
- 6.1.6 Merck & Co. Inc.
- 6.1.7 Merck KGaA (Sigma Aldrich)
- 6.1.8 Pfizer Inc.
- 6.1.9 Rare Disease Therapeutics Inc.
- 6.1.10 South African Vaccine Producers (Pty) Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAnti-Venom Industry Segmentation
As per the scope of the report, An anti-venom (or antivenin or antivenene) is a biological product used to treat venomous bites or stings. The anti-venom is created by extracting venom from the relevant species of animal, which includes snakes, spiders, insects, fish, etc. The Anti-venom Market is Segmented by Species (Snake, Scorpion, Spiders, and Other Species), Anti-venom Type (Polyvalent Anti-venoms, Monovalent Anti-venom, and Other Anti-venom Types), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the market size and forecasts in value (USD million) for the above segments.
| By Species | Snake | |
| Scorpion | ||
| Spiders | ||
| Other Species | ||
| By Anti-venom Type | Polyvalent Anti-venoms | |
| Monovalent Anti-venom | ||
| Other Anti-venom Types | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Anti-Venom Market Research FAQs
How big is the Anti-venom Market?
The Anti-venom Market size is expected to reach USD 1.20 billion in 2024 and grow at a CAGR of 3.13% to reach USD 1.40 billion by 2029.
What is the current Anti-venom Market size?
In 2024, the Anti-venom Market size is expected to reach USD 1.20 billion.
Who are the key players in Anti-venom Market?
Pfizer Inc., Merck KGaA (Sigma Aldrich), Boehringer Ingelheim, CSL Limited and Bharat Serums and Vaccines Ltd are the major companies operating in the Anti-venom Market.
Which is the fastest growing region in Anti-venom Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Anti-venom Market?
In 2024, the North America accounts for the largest market share in Anti-venom Market.
What years does this Anti-venom Market cover, and what was the market size in 2023?
In 2023, the Anti-venom Market size was estimated at USD 1.16 billion. The report covers the Anti-venom Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Anti-venom Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Anti Venom Industry Report
Statistics for the 2024 Anti Venom market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Anti Venom analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
